Advertisement

Liver Diseases pp 667-672 | Cite as

Embolization Therapy for Liver Cancer

  • Lukas LuerkenEmail author
  • Lukas Beyer
Chapter

Abstract

Transarterial chemoembolization (TACE) is a relatively new endovascular treatment based on the minimally invasive induction of tumor necrosis by a high local concentration of a chemotherapeutic agent and an embolic effect. The embolic effect causes ischemia on the one hand and an increased local dwell time of the chemotherapeutic agent in the tumor on the other. Nowadays TACE represents one of the most used treatments for unresectable hepatocellular carcinoma and is the treatment of first choice for patients with intermediate HCC stage BCLC B. However, there is no consensus about the choice of the best embolotherapy technique.

Keywords

Liver cancer HCC Colorectal cancer Interventional oncology Embolization 

References

  1. 1.
    Hidaka H, Kobayashi H, Ohyama M, et al. Transarterial chemoembolization therapy of hepatocellular carcinoma using anticancer agents (mitomycin C and/or adriamycin) suspended in lipiodol. Nihon Igaku Hoshasen Gakkai zasshi Nippon acta radiologica. 1985;45(11):1430–40.PubMedGoogle Scholar
  2. 2.
    European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182. https://www.sciencedirect.com/science/article/pii/S0168827818302150. Accessed January 31, 2019.CrossRefGoogle Scholar
  3. 3.
    Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.  https://doi.org/10.1055/s-2007-1007122.CrossRefPubMedGoogle Scholar
  4. 4.
    Raoul J-L, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–20.  https://doi.org/10.1016/j.ctrv.2010.07.006.CrossRefPubMedGoogle Scholar
  5. 5.
    Frangakis C, Geschwind J-F, Kim D, et al. Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list. Cardiovasc Intervent Radiol. 2011;34:1254–61.  https://doi.org/10.1007/s00270-010-0077-7.CrossRefPubMedGoogle Scholar
  6. 6.
    Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013;19:7515–30.  https://doi.org/10.3748/wjg.v19.i43.7515.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One. 2017;12:e0170750.  https://doi.org/10.1371/journal.pone.0170750.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14:810.  https://doi.org/10.1186/1471-2407-14-810.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Massmann A, Rodt T, Marquardt S, et al. Transarterial chemoembolization (TACE) for colorectal liver metastases--current status and critical review. Langenbecks Arch Surg. 2015;400:641–59.  https://doi.org/10.1007/s00423-015-1308-9.CrossRefPubMedGoogle Scholar
  10. 10.
    Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16.CrossRefGoogle Scholar
  11. 11.
    Stone PA, Campbell JE. Complications related to femoral artery access for transcatheter procedures. Vasc Endovascular Surg. 2012;46:617–23.  https://doi.org/10.1177/1538574412457475.CrossRefPubMedGoogle Scholar
  12. 12.
    Lupattelli T, Clerissi J, Clerici G, et al. The efficacy and safety of closure of brachial access using the AngioSeal closure device: experience with 161 interventions in diabetic patients with critical limb ischemia. J Vasc Surg. 2008;47:782–8.  https://doi.org/10.1016/j.jvs.2007.11.050.CrossRefPubMedGoogle Scholar
  13. 13.
    Valgimigli M, Gagnor A, Calabró P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385:2465–76.  https://doi.org/10.1016/S0140-6736(15)60292-6.CrossRefPubMedGoogle Scholar
  14. 14.
    Patel VG, Brayton KM, Kumbhani DJ, Banerjee S, Brilakis ES. Meta-analysis of stroke after transradial versus transfemoral artery catheterization. Int J Cardiol. 2013;168:5234–8.  https://doi.org/10.1016/j.ijcard.2013.08.026.CrossRefPubMedGoogle Scholar
  15. 15.
    Miyayama S, Yamashiro M, Ikuno M, Okumura K, Yoshida M. Ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinoma guided by automated tumor- feeders detection software: technical success and short-term tumor response. Abdom Imaging. 2014;39(3):645–56.CrossRefGoogle Scholar
  16. 16.
    Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.  https://doi.org/10.1148/radiol.2241011262.CrossRefPubMedGoogle Scholar
  17. 17.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology (Baltimore, Md). 2003;37:429–42.  https://doi.org/10.1053/jhep.2003.50047.CrossRefGoogle Scholar
  18. 18.
    Kirstein MM, Voigtländer T, Schweitzer N, Hinrichs JB, Marquardt J, Wörns MA, Kloeckner R, Fründt TW, Ittrich H, Wacker F, Rodt T, Manns MP, Wege H, Weinmann A, Vogel A. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. U Eur Gastroenterol J. 2018;6(2):238–46.CrossRefGoogle Scholar
  19. 19.
    Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–16.CrossRefGoogle Scholar
  20. 20.
    Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology. 2017;Google Scholar
  21. 21.
    Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.CrossRefGoogle Scholar
  22. 22.
    Ronot M, Abdel-Rehim M, Hakimé A, Kuoch V, Roux M, Chiaradia M, et al. Cone-beam CT angiography for determination of tumor-feeding vessels during chemoembolization of liver tumors: comparison of conventional and dedicated-software analysis. J Vasc Interv Radiol. 2016;27:32–8.CrossRefGoogle Scholar
  23. 23.
    Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):1330–5.CrossRefGoogle Scholar
  24. 24.
    Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.CrossRefGoogle Scholar
  25. 25.
    Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64.CrossRefGoogle Scholar
  26. 26.
    Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep. 2004;11:1077–84.PubMedGoogle Scholar
  27. 27.
    Håkansson L, Håkansson A, Morales O, Thorelius L, Warfving T. Spherex (degradable starch microspheres) chemo-occlusion—enhancement of tumor drug concentration and therapeutic efficacy: an overview. Semin Oncol. 1997;24:S6–100–S6-109.PubMedGoogle Scholar
  28. 28.
    Schicho A, Pereira PL, Haimerl M, et al. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy. Oncotarget. 2017;8:72613–20.Google Scholar
  29. 29.
    Orlacchio A, Chegai F, Francioso S, et al. Repeated transarterial chemoembolization with degradable starch microspheres (DSMs-TACE) of unresectable hepatocellular carcinoma: a prospective pilot study. Curr Med imag Rev. 2018;14:637–45.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of RadiologyUniversity Hospital RegensburgRegensburgGermany

Personalised recommendations